Invivyd's COVID-19 Antibody Shows Favorable Safety, Tolerability Profile For Immunocompromised People
Portfolio Pulse from Vandana Singh
Invivyd Inc (NASDAQ:IVVD) has released additional initial data from its ongoing Phase 1 clinical trial of its lead investigational monoclonal antibody (mAb) candidate, VYD222. The data shows that a single administration of VYD222 was generally well-tolerated at all three dose levels tested, with no serious adverse events reported. The company intends to use these analyses to further inform its VYD222 dosing strategy.
July 17, 2023 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Invivyd's positive initial data from its Phase 1 trial of VYD222 could boost investor confidence in the company's COVID-19 prevention strategy.
The positive initial data from Invivyd's Phase 1 trial of VYD222 indicates that the drug is generally well-tolerated and safe. This could boost investor confidence in the company's COVID-19 prevention strategy, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100